Engineered immune cells take on pancreatic cancer in early trial
NCT ID NCT03323944
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a treatment called huCART-meso cells, which are a patient's own immune cells modified to recognize and attack pancreatic cancer cells. The trial included 54 people with advanced pancreatic cancer that could not be removed by surgery. The main goal was to check safety and see if the approach is feasible, with some participants receiving the cells through an IV and others directly into the abdomen or liver.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
huCART-meso cells (a type of immune cell therapy)
What this could lead to
If successful, this could point toward a new treatment option for pancreatic cancer using the body's own immune cells.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not effectiveness. The study was terminated, so results may be limited. Side effects from CAR T cells can be severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States